Emisphere Technologies, Inc. reported unaudited earnings results for the third quarter and nine months ended of September 30, 2015. For the quarter, the company's revenue was $130,000 compared to no revenue for the third quarter ended September 30, 2014. The increase in revenue was due to sales revenues from Eligen B12, which was launched in March 2015. The company reported a net loss of $4.4 million, or $0.07 per basic and diluted share, compared to net loss of $14.4 million, or $0.24 per basic and diluted share, for the same period last year. Operating loss was $4,668,000 compared to $2,120,000 a year ago. Net loss before tax incentive was $4,422,000 compared to $14,373,000 a year ago.

For the year to date, the company's revenue was $225,000 compared to no revenue for the nine months ended September 30, 2014. The increase in revenue was due to sales revenues from Eligen B12. The company reported a net loss of $30.3 million, or $0.50 per basic and diluted share, compared to net loss of $25.8 million, or $0.43 per basic and diluted share, for the same period last year. Operating loss was $13,900,000 compared to $6,004,000 a year ago. Net loss before tax incentive was $30,254,000 compared to $27,483,000 a year ago.